Skip to main content

Market Overview

The Week Ahead In Biotech: J&J Vaccine Adcom Meeting, Sarepta FDA Decision And Plenty Of Earnings

The Week Ahead In Biotech: J&J Vaccine Adcom Meeting, Sarepta FDA Decision And Plenty Of Earnings

Biotech stocks pulled back along with the broader market in the holiday-shortened week ended Feb 19. Earnings news flow was light before picking up pace in the unfolding week.

Bluebird bio Inc (NASDAQ: BLUE) was among the worst performers of the week after the company temporarily stalled its gene therapy studies in sickle cell disease.

A day after bluebird bio shared the negative tidings, Novartis AG (NYSE: NVS) announced an agreement with the Bill & Melinda Gates Foundation for funding the development of a single-administration, in-vivo gene therapy to cure sickle cell disease.

The week also witnessed the forging of a few alliances and partnerships, a slew of follow-on offerings and some vaccine updates.

Here are the key catalytic events for the coming week:


Annual SVB Leerink Global Healthcare Conference (virtual event): Feb. 22-26

Citi Healthcare Services Virtual Conference (virtual event): Feb. 24-25

Americas Committee for Treatment and Research in Multiple Sclerosis, or ACTRIMS, Forum (virtual event): Feb. 25-27


The Food and Drug Administration is scheduled to rule on Sarepta Therapeutics Inc's (NASDAQ: SRPT) new drug application for casimersen, a treatment for patients with Duchenne muscular dystrophy who have certain genetic mutations. The PDUFA goal date is Thursday, Feb. 25.

Clinical Readouts

ACTRIMS Presentation:

Clene Inc. (NASDAQ: CLNN): updated interim Phase 2 data from the REPAIR-MS study evaluating CNM-Au8 in relapsing multiple sclerosis and updated blinded interim Phase 2 data from the VISIONARY-MS study of CNM-Au8 in chronic optic neuropathy



AxoGen, Inc Common Stock (NASDAQ: AXGN) (after the market close)
Pulse Biosciences Inc (NASDAQ: PLSE) (after the market close)
PAVmed Inc (NASDAQ: PAVM) (after the market close)
Revance Therapeutics Inc (NASDAQ: RVNC) (after the market close)
Plus Therapeutics Inc (NASDAQ: PSTV) (after the market close)


Rubius Therapeutics Inc (NASDAQ: RUBY) (before the market open)
Epizyme Inc (NASDAQ: EPZM) (before the market open)
Clovis Oncology Inc (NASDAQ: CLVS) (before the market open)
Adamas Pharmaceuticals Inc (NASDAQ: ADMS) (after the close)
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) (after the close)
AtriCure Inc. (NASDAQ: ATRC) (after the close)
Theravance Biopharma Inc (NASDAQ: TBPH) (after the close)
Masimo Corporation (NASDAQ: MASI) (after the close)
Insulet Corporation (NASDAQ: PODD) (after the close)
Esperion Therapeutics Inc (NASDAQ: ESPR) (after the close)
Myriad Genetics, Inc. (NASDAQ: MYGN) (after the close)
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (after the close)
Inspire Medical Systems Inc (NYSE: INSP) (after the close)
Penumbra Inc (NYSE: PEN) (after the close)
Xencor Inc (NASDAQ: XNCR) (after the close)
Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) (after the close)
MacroGenics Inc (NASDAQ: MGNX) (after the close)
Medtronic PLC(NYSE: MDT) (after the close)


SAGE Therapeutics Inc (NASDAQ: SAGE) (before the market open)
Merit Medical Systems, Inc. (NASDAQ: MMSI) (before the market open)
United Therapeutics Corporation (NASDAQ: UTHR) (before the market open)
Xtant Medical Holdings Inc (NYSE: XTNT) (before the market open)
Horizon Therapeutics PLC (NASDAQ: HZNP) (before the market open)
Repligen Corporation (NASDAQ: RGEN) (before the market open)
Kura Oncology Inc (NASDAQ: KURA) (before the market open)w
NeoGenomics, Inc. (NASDAQ: NEO) (before the market open)
Ionis Pharmaceuticals Inc (NASDAQ: IONS) (before the market open)
PPD Inc (NASDAQ: PPD) (before the market open)
Vericel Corp (NASDAQ: VCEL) (before the market open)
Harvard Bioscience, Inc. (NASDAQ: HBIO) (before the market open)
Adaptive Biotechnologies Corp (NASDAQ: ADPT) (after the close)
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) (after the close)
Alimera Sciences Inc (NASDAQ: ALIM) (after the close)
Global Blood Therapeutics Inc (NASDAQ: GBT) (after the close)
Coherus Biosciences Inc (NASDAQ: CHRS) (after the close)
Nevro Corp (NYSE: NVRO) (after the close)
CareDx Inc (NASDAQ: CDNA) (after the close)
CytomX Therapeutics Inc (NASDAQ: CTMX) (after the close)
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) (after the close)
Paratek Pharmaceuticals Inc (NASDAQ: PRTK) (after the close)
Tandem Diabetes Care Inc (NASDAQ: TNDM) (after the close)
Guardant Health Inc (NASDAQ: GH) (after the close)
G1 Therapeutics Inc (NASDAQ: GTHX) (after the close)

Related Link: Vir Biotech Expands Vaccine Collaboration With GlaxoSmithKline: What You Need to Know


Chimerix Inc (NASDAQ: CMRX) (before the market open)
Concert Pharmaceuticals Inc (NASDAQ: CNCE) (before the market open)
Kala Pharmaceuticals Inc (NASDAQ: KALA) (before the market open)
Jounce Therapeutics Inc (NASDAQ: JNCE) (before the market open)
Intellia Therapeutics Inc (NASDAQ: NTLA) (before the market open)
Moderna Inc (NASDAQ: MRNA) (before the market open)
Radius Health Inc (NASDAQ: RDUS) (before the market open)
Insmed Incorporated (NASDAQ: INSM) (before the market open)
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) (before the market open)
Editas Medicine Inc (NASDAQ: EDIT) (before the market open)
Mediwound Ltd (NASDAQ: MDWD) (before the market open)
Novocure Ltd (NASDAQ: NVCR) (before the market open)
Glaukos Corp (NYSE: GKOS) (before the market open)
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) (before the market open)
Pacira Biosciences Inc (NASDAQ: PCRX) (before the market open)
Provention Bio Inc (NASDAQ: PRVB) (before the market open)
Albireo Pharma Inc (NASDAQ: ALBO) (before the market open)
Amarin Corporation plc (NASDAQ: AMRN) (before the market open)
Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP) (before the market open)
Akebia Therapeutics Inc (NASDAQ: AKBA) (before the market open)
Agios Pharmaceuticals Inc (NASDAQ: AGIO) (before the market open)
Aerie Pharmaceuticals Inc (NASDAQ: AERI) (after the close)
Apellis Pharmaceuticals Inc (NASDAQ: APLS) (after the close)
Acceleron Pharma Inc (NASDAQ: XLRN) (after the close)
Allogene Therapeutics Inc (NASDAQ: ALLO) (after the close)
Puma Biotechnology Inc (NASDAQ: PBYI) (after the close)
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) (after the close)
Caladrius Biosciences Inc (NASDAQ: CLBS) (after the close)
Iovance Biotherapeutics Inc (NASDAQ: IOVA) (after the close)
Intra-Cellular Therapies Inc (NASDAQ: ITCI) (after the close)
Nektar Therapeutics (NASDAQ: NKTR) (after the close)
Natera Inc (NASDAQ: NTRA) (after the close)
ICU Medical Inc (NASDAQ: ICUI) (after the close)
Zogenix, Inc. (NASDAQ: ZGNX) (after the close)
NuVasive, Inc. (NASDAQ: NUVA) (after the close)
ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) (after the close)
PRA Health Sciences Inc (NASDAQ: PRAH) (after the close)
Endo International PLC (NASDAQ: ENDP) (after the close)
Lantheus Holdings Inc (NASDAQ: LNTH) (after the close)
TRACON Pharmaceuticals Inc (NASDAQ: TCON) (after the close)
PTC Therapeutics, Inc. (NASDAQ: PTCT) (after the close)
LeMaitre Vascular Inc (NASDAQ: LMAT) (after the close)
Voyager Therapeutics Inc (NASDAQ: VYGR) (after the close)
Natus Medical Inc (NASDAQ: NTUS) (after the close)
Cerus Corporation (NASDAQ: CERS) (after the close)
Dynavax Technologies Corporation (NASDAQ: DVAX) (after the close)
Cytokinetics, Inc. (NASDAQ: CYTK) (after the close)
Collegium Pharmaceutical Inc (NASDAQ: COLL) (after the close)
GenMark Diagnostics, Inc (NASDAQ: GNMK) (after the close)
Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) (after the close)
Vir Biotechnology Inc (NASDAQ: VIR) (after the close)


Amneal Pharmaceuticals Inc (NYSE: AMRX) (before the market open)
Orthofix Medical Inc (NASDAQ: OFIX) (before the market open)

IPO Quiet Period Expiries

Ortho Clinical Diagnostics Holdings PLC (NASDAQ: OCDX)
NLS Pharmaceutics AG (NASDAQ: NLSP)

Other Events

Viatris Inc (NASDAQ: VTRS) has scheduled a conference call Monday, at 8 a.m., to discuss the generic pharma company's 2021 guidance.

FDA's Vaccine & Related Biological Products Committee is scheduled to meet Friday, Feb. 26, between 9 a.m. and 5:30 p.m., to discuss Johnson & Johnson (NYSE: JNJ) unit Janssen's emergency use authorization application for its COVID-19 vaccine.

Related Link: Lilly Strikes Licensing Deal With Rigel In Push Toward Neurological, Immunological Therapies


Related Articles (IBB)

View Comments and Join the Discussion!

Posted-In: Biotech Earnings News Penny Stocks Previews Small Cap FDA Trading Ideas Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at